Metagenomi reports Q2 2026 results, stays on track for MGX-001 hemophilia A IND filing

Metagenomi Therapeutics said on August 10, 2026 that it expects IND-enabling studies for MGX-001, its hemophilia A program, to be complete by the end of the third quarter of 2026, including GLP toxicity work.¹ The company remains on track to submit an IND application in the fourth quarter of 2026 for the global clinical program, and subject to regulatory clearance, plans to initiate clinical trials in 2027.¹

Metagenomi also noted recognition for its preclinical data. Two Metagenomi scientific posters received Top Poster Awards at the 2026 International Society on Thrombosis and Haemostasis (ISTH) Congress in Paris, France, including one highlighting extensive non-human primate preclinical data supporting MGX-001.¹

On its second pipeline effort, the company said it continues to evaluate disease indications that could be treated by protein replacement via gene insertion using its large gene integration system.¹

CEO Jian Irish said the company is continuing to execute against its strategic priorities while advancing toward planned regulatory submissions for MGX-001 in hemophilia A later in the year, and is engaging with hemophilia investigators and key opinion leaders to prepare for its first-in-human study.¹

On finances, Metagenomi reported $120.7 million in cash, cash equivalents, and available-for-sale marketable securities as of June 30, 2026.¹ The company said this runway is anticipated to support operations through the fourth quarter of 2027.¹

The company describes MGX-001 as its lead, wholly-owned development program in hemophilia A, with a preclinical profile the company describes as having best-in-class treatment potential, including targeted genome editing and durable gene expression in a one-time treatment.¹ It also said it is pursuing indications leveraging the MGX-001 site-specific genome integration system and partnered assets targeting cardiometabolic diseases.¹